免責事項: 本サイトは、FDA、ClinicalTrials.gov、PubMed、SEC EDGAR などの公式公開データを一般参考用に集約するものであり、医学的助言、診断、治療推奨、投資助言を構成しません。

PubMed

[Programmed Medical Device (SaMD) and Orphan Drug Innovation Processes and Industrial Systems].

PMID: 41485960 · 2026

R, e, i, , G, o, t, o, ;, , S, h, i, n, t, a, r, o, , S, e, n, g, o, k, u, ;, , K, o, t, a, , K, o, d, a, m, a

学術誌Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
年2026
PMID41485960

抄録

The innovation patterns and institutional environments of software as a medical device (SaMD) were empirically, comparatively, and institutionally analyzed as SaMD is attracting attention as innovative medical technology. Data were collected on SaMD products approved by the U.S. Food and Drug Administration (FDA) and medical providers (n=581 and 268, respectively). The relationships among SaMD use, the interaction of SaMD with existing medical devices, and company characteristics were structural

公式ソース

PubMedで見る →

データはPubMed / NCBIから取得しています。全文および最新情報は必ず公式記録をご確認ください。

↑